Laurie Toich, Assistant Editor

Top news of the day from across the healthcare landscape.

CVS Health expands access to drug that reverses opioid overdoses.

Brilinta did not outperform clopidogrel in patients with symptomatic peripheral artery disease.

The FDA grants autoimmune condition drug additional Breakthrough Therapy Designation.

FDA grants Roche’s drug Alecensa another Breakthrough Therapy Designation.

Approximately 40% of whites and 50% of blacks over 45-years-old developed high blood pressure over 10 years.

Alecensa found to increase progression-free survival in ALK-positive non-small cell lung cancer compared with crizotinib.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

Medicare will implement an experimental medication therapy management model for several Part D plan sponsors.

Allergan plans to acquire AstraZeneca’s MEDI2070, for moderate-to-severe Crohn’s disease, ulcerative colitis and related conditions.

Yosparla prevents secondary cardiovascular events while preventing aspirin-associated gastric ulcers.

Alcohol consumption may cause heart damage that leads to atrial fibrillation.

Top news of the day from across the healthcare landscape.

AbbVie’s experimental drug can treat hepatitis C virus genotypes 1 through 6.

FDA issues boxed warning that hepatitis C direct-acting antivirals may cause hepatitis B to reactivate in coinfected patients.

Experimental hepatitis C medication treats genotypes 1 through 6.

An independent organization and additional funding may improve healthcare transparency.

Direct-acting antivirals may cause hepatitis B reactivation in patients with an HCV/HBV co-infection.

New recommendations seek to improve cost-effective care analysis.

Top news of the day from across the healthcare landscape.

New research explores the difference between statins and PCSK9 inhibitors.

Spending on specialty drugs for autoimmune conditions now account for 10% of drug expenses.

The Harrison School of Pharmacy started a free training program for assisting Medicare beneficiaries eligible for subsidies.

Aetna will offer subsidies for consumers to purchase an Apple Watch.

Top news of the day from across the healthcare landscape.

Prime Therapeutics initiative prevents Medicare beneficiaries from refilling high-risk medications.

Top news of the day from across the healthcare landscape.

Dupilumab is an investigational antibody treatment for inadequately controlled moderate-to-severe atopic dermatitis.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.